CISA published advisory ICSMA-22-263-01 on September 20, 2022, covering CVE-2022-32537 in Medtronic's NGP 600 series insulin pumps. Affected are the MiniMed 620G, 630G, 640G and 670G across a set of MMT model numbers. Medtronic reported the issue itself.
The flaw is a protection mechanism failure (CWE-693) in pairing. While the pump is being paired with other system components, an unauthorized user could learn aspects of the communication protocol those components use.
The consequence is clinical. Per the risk evaluation, successful exploitation could let an unauthorized user deliver too much or too little insulin, either through an unintended bolus or by slowing or stopping delivery.
The bar is high, which is why the CVSS v3 score is only 4.8. The attacker needs nearby wireless signal proximity to the patient and the device, low privileges and advanced technical knowledge, and has to catch the pairing window. The vector rates integrity impact high and confidentiality and availability none.
Medtronic's precautions center on the remote bolus feature: turning it off ensures no remote bolus is possible. Pairing is the moment a therapy device is most exposed, so do it somewhere private and keep it short.